Milestones
1999
1999
LifeTech Scientific Corporation was established in Shenzhen, China
2001
2001
HeartR™ PDA Occluder was approved by NMPA in China, becoming the first product successfully marketed by the company
2003
2003
HeartR™ ASD Occluder was approved by NMPA in China
2004
2004
Ankura™ TAA\AAA Stent Graft System and HeartR™ VSD Occluder were approved by NMPA in China
2005
2005
Aegisy™ Vena Cava Filter was approved by NMPA in China
2006
2006
The company received a venture capital investment from the United States
SteerEase™ Introducer was approved by NMPA in China
2008
2008
The company was accredited as a national high-tech enterprise in China
The company expanded its business into India market and incorporated Lifetech Scientific India Private Limited into the LifeTech family
2009
2009
Aegisy™ Vena Cava Filter obtained the CE mark in EU, becoming the first product of the company to receive one
Cera™ Occluder series and SteerEase™ Introducer obtained the CE mark in EU
2010
2010
SeQure™ Snare System received FDA approval in the United States, becoming the first product of the company to receive one
Fustar™ Steerable Introducer, Cera™ Vascular Plug System, Acumark™ Sizing Balloon, Cera™ Multi-Fenestrated ASD Occluder and SeQure™ Snare System obtained the CE mark in EU
2011
2011
LifeTech Scientific Corporation was listed on the Hong Kong Stock Exchange (Stock Code: 1302.HK)
The company incorporated LifeTech Scientific (Europe) Coöperatief U.A. to further explore the European market
Fustar™ Steerable Introducer received FDA approval in the United States
CeraFlex™ Occluder series and Vascular Plugs, Ankura™ Stent Graft System obtained the CE mark in EU
2012
2012
The company established a strategic partnership with Medtronic, Inc.
The company incorporated LifeTech Scientific (Netherlands) B.V. into the LifeTech family
Cera™ PDA Occluder and ASD Occluder were approved by NMPA in China
HeartR™ Occluder series, Cera™/CeraFlex™/IrisFit™ PFO Occluders and LawMax™ Dilator obtained the CE mark in EU
2013
2013
Cera™ VSD Occluder was approved by NMPA in China
LawMax™ Dilator received FDA approval in the United States
2014
2014
Fustar™ Steerable Introducer was approved by NMPA in China
2015
2015
The company has been included in the Hang Seng Index
The company incorporated Lifetech Scientific America Corporation to add to its list of international subsidiaries
2016
2016
The company has been included in the Shenzhen-Hong Kong Stock Connect Programs
The company established a subsidary in Hong Kong and Greece, respectively
LAmbre™ LAA Closure System and GoldenFlow™ Peripheral Bare Stent System obtained the CE mark in EU
SteerNavi™ Introducer was approved by NMPA in China
2017
2017
The company commercialized HeartTone™ Implantable Cardiac Pacemakers in China market with the cooperation of Medtronic Inc.
LAmbre™ LAA Closure System, SeQure™ Snare System, LawMax™ Dilator and Ankura™ II Stent Graft System were approved by NMPA in China
2018
2018
The company established a strategic partnership with Ally Bridge Group, a global life science-focused investment firm
KONAR-MF™ VSD Occluder obtained the CE mark in EU
2019
2019
The company established a joint venture (JV) with Quantum Surgical SAS and Ally Bridge Group for commercialization of the Epione®, a new category of oncology robotics in China market
The company incorporated LifeTech Scientific Deutschland GmbH to further expand its business in the heart of Europe
LAmbre™ LAA Closure System obtained FDA approval for the pre-market clinical study in the United States
Aelark™ Vena Cava Filter System was approved by NMPA in China
2020
2020
LAmbre™ LAA Closure System obtained FDA approval for an investigator-initiated pre-market clinical trial in the United States
HeartR™ II ASD Occluder, Fustar™ mini Steerable Catheter, FiQure™ Vena Cava Filter Retrieval System, ZoeTrack™ Guidewire, FemCross™ 18 Peripheral Balloon Dilatation Catheter, Futhrough™ Stent Graft Balloon Catheter were approved by NMPA in China
Futhrough™ Endovascular Needle System obtained the CE mark in EU
2021
2021
The invention patent “LAA Occluder” won the WIPO-CNIPA Award for Chinese Outstanding Patented Invention
The company and Medtronic Inc. expanded strategic collaboration to open a new chapter of domestically-made MRI-conditional pacemakers in China
G-iliac™ Iliac Artery Bifurcation Stent Graft System, Yuranos™ Abdominal Aortic Stent Graft System, LAxible™ LAA Occluder, LAnavi™ Jointed Steerable Introducer, OKcurve™ Steerable Delivery System, Freepath™ Guidance System and iCable™ Delivery Cable were approved by NMPA in China
IBS Angel™ Iron Bioresorbable Scaffold System obtained registration approval from Malaysian Medical Device Authority (MDA)
Xuper™ Open Surgery Stent Graft System obtained the CE mark in EU
2022
2022
An FDA-approved investigator-initiated pre-market clinical trial of LAmbre™ Plus LAA Closure System obtained medical insurance coverage in the United States
Fitaya™ Vena Cava Filter System, FemCross™ 35 Peripheral Balloon Dilatation Catheter and Ankura™ llc Stent Graft System were approved by NMPA in China
2023
2023
IBS Angel™ Iron Bioresorbable Scaffold System obtained CE MDR certification in EU
Peripheral Thrombus Aspiration Catheter, AcuMark™ Sizing Balloon and Epione® Surgical Navigation System were approved by NMPA in China